Abstract
Rapamycin, a potent inhibitor of the mammalian target of rapamycin (mTOR) protein kinase, is a well-known immunosuppressive agent. In this issue, Wu and colleagues report that rapamycin significantly attenuates renal interstitial fibrosis in obstructive nephropathy. Besides its inhibition of renal inflammation, rapamycin is able to block tubular epithelial-mesenchymal transition, thereby shedding new light on the mechanism of its antifibrotic actions. © 2006 International Society of Nephrology.
Cite
CITATION STYLE
Liu, Y. (2006). Rapamycin and chronic kidney disease: Beyond the inhibition of inflammation. Kidney International. Nature Publishing Group. https://doi.org/10.1038/sj.ki.5001543
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.